158 related articles for article (PubMed ID: 18790773)
1. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
[TBL] [Abstract][Full Text] [Related]
2. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
[TBL] [Abstract][Full Text] [Related]
4. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
[TBL] [Abstract][Full Text] [Related]
6. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
[TBL] [Abstract][Full Text] [Related]
8. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S
Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103
[TBL] [Abstract][Full Text] [Related]
9. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
[TBL] [Abstract][Full Text] [Related]
10. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells.
Hetzel C; Bachran C; Fischer R; Fuchs H; Barth S; Stöcker M
J Immunother; 2008 May; 31(4):370-6. PubMed ID: 18391759
[TBL] [Abstract][Full Text] [Related]
11. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
12. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
[TBL] [Abstract][Full Text] [Related]
13. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
[TBL] [Abstract][Full Text] [Related]
14. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation.
Krasinskas AM; Wasik MA; Kamoun M; Schretzenmair R; Moore J; Salhany KE
Am J Clin Pathol; 1998 Dec; 110(6):797-805. PubMed ID: 9844593
[TBL] [Abstract][Full Text] [Related]
17. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.
Mathew M; Zaineb KC; Verma RS
Apoptosis; 2013 Jul; 18(7):882-95. PubMed ID: 23529188
[TBL] [Abstract][Full Text] [Related]
18. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
19. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T
Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033
[TBL] [Abstract][Full Text] [Related]
20. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation.
Yong SB; Kim HJ; Kim JK; Chung JY; Kim YH
Sci Rep; 2017 Feb; 7():42171. PubMed ID: 28169353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]